The mitochondrial phosphate carrier (PiC) is critical for ATP synthesis by serving as the primary means for mitochondrial phosphate import across the inner membrane. In addition to its role in energy production, PiC is hypothesized to have a role in cell death as either a component or a regulator of the mitochondrial permeability transition pore (MPTP) complex. Here, we have generated a mouse model with inducible and cardiac-specific deletion of the Slc25a3 gene (PiC protein). Loss of PiC protein did not prevent MPTP opening, suggesting it is not a direct pore-forming component of this complex. However, Slc25a3 deletion in the heart blunted MPTP opening in response to Ca 2 þ challenge and led to a greater Ca 2 þ uptake capacity. This desensitization of MPTP opening due to loss or reduction in PiC protein attenuated cardiac ischemic-reperfusion injury, as well as partially protected cells in culture from Ca 2 þ overload induced death. Intriguingly, deletion of the Slc25a3 gene from the heart long-term resulted in profound hypertrophy with ventricular dilation and depressed cardiac function, all features that reflect the cardiomyopathy observed in humans with mutations in SLC25A3. Together, these results demonstrate that although the PiC is not a direct component of the MPTP, it can regulate its activity, suggesting a novel therapeutic target for reducing necrotic cell death. In addition, mice lacking Slc25a3 in the heart serve as a novel model of metabolic, mitochondrial-driven cardiomyopathy. The mitochondrial oxidative phosphorylation (OXPHOS) system is the primary source of cellular energy production. Defects in OXPHOS occur with a frequency of 1 in 5000 live births 1 and underlie a wide range of mitochondrial disorders that often affect multiple organ systems and tissues with high oxidative energy demands, such as brain, skeletal muscle, and heart.
The mitochondrial oxidative phosphorylation (OXPHOS) system is the primary source of cellular energy production. Defects in OXPHOS occur with a frequency of 1 in 5000 live births 1 and underlie a wide range of mitochondrial disorders that often affect multiple organ systems and tissues with high oxidative energy demands, such as brain, skeletal muscle, and heart. 2 Cardiac phenotypes associated with mitochondrial disease are diverse, and can range from cardiomyopathies to cardiac conduction defects. [3] [4] [5] The mitochondrial phosphate carrier (PiC) is a member of the solute carrier 25A family that has a critical role in OXPHOS, serving as the primary route for inorganic phosphate (Pi) import into the mitochondrial matrix. 6, 7 PiC, together with the adenine nucleotide translocator (ANT) and the ATP synthase, forms the ATP synthasome whereby all of the metabolites needed to generate ATP are within one immediate microdomain. 8, 9 The importance of PiC in facilitating energy production is highlighted by the profound disease phenotype observed in patients presenting with mutations in the skeletal muscle-specific isoform of this gene. 10, 11 Such patients present with a multisystemic disorder characterized by muscle hypotonia, lactic acidosis, severe hypertrophic cardiomyopathy, and shortened lifespan. 10, 11 Similarly, patients with SLC25A4 (ANT1 protein) deficiency present with cardiomyopathy, 12 as do mice lacking the Slc25a4 gene, 13 likely due to a similar molecular defect in the efficiency of ATP production within the mitochondria.
In addition to its role in mitochondrial energy metabolism, PiC has been implicated in regulating cell death by serving either as a modulator or a direct component of the mitochondrial permeability transition pore (MPTP). [14] [15] [16] The MPTP is a nonselective channel that forms in response to Ca 2 þ overload and oxidant stress that allows inner-membrane permeability to solutes up to 1500 Da in size, leading to loss of mitochondrial membrane potential, mitochondrial swelling and rupture, and eventually cell death through necrosis. 15 Structurally, the MPTP complex has been proposed to be comprised of the ATP synthase 17, 18 and to be regulated by cyclophilin D (CypD), 19, 20 ANT, 21 and the pro-apoptotic proteins Bax and Bak in the outer mitochondrial membrane. 22, 23 PiC has also been suggested to be an inner-membrane component of the MPTP because it can form nonspecific channels in lipid membranes and because the MPTP is known to be activated by Pi. [24] [25] [26] [27] Finally, PiC directly interacts with CypD in the mitochondrial matrix, which is a verified regulator and component of the MPTP. 16 Saccharomyces cerevisiae lacking PiC have altered MPTP characteristics with a smaller pore size, suggesting it might directly participate in the mitochondrial permeability pore. 28 However, partial reduction of PiC by siRNAs in cultured cells had no effect on mitochondrial permeability activity, suggesting that PiC is not required for MPTP function. 27 Definitive genetic proof of PiC's involvement in MPTP formation/ function is currently lacking.
In the present study, we tested the role of PiC in MPTP regulation and cell death in vivo using a mouse model with inducible cardiomyocyte-specific deletion of the Slc25a3 gene (encodes PiC). We found that cardiac mitochondria depleted of PiC were able to undergo permeability transition, suggesting that PiC is not a requisite component of the MPTP. However, the extent of Ca 2 þ -induced MPTP opening was blunted, suggesting that PiC serves to regulate this activity. Furthermore, Slc25a3 deletion produced a unique mouse model of mitochondrial-driven hypertrophic cardiomyopathy that recapitulates features observed in human patients with phosphate carrier deficiency and metabolic cardiomyopathy.
Results
Generation of mice with an inducible cardiac myocytespecific deletion of Slc25a3. To determine the necessary role of PiC in the heart, gene-targeted mice were generated from embryonic stem cells in which the Slc25a3 genetic locus was targeted with a DNA vector that after homologous recombination resulted in the placement of loxP sites (fl) flanking exons 1 and 2, to permit future conditional disruption of this gene in the mouse heart ( Figure 1a) . Inducible cardiac-specific deletion of Slc25a3 was achieved by crossing Slc25a3 fl/fl mice with transgenic mice expressing a tamoxifen-induced Cre protein, referred to as MerCreMer (MCM), under the regulation of the a-myosin heavy-chain (a-MHC) promoter (Slc25a3 fl/fl-MCM ). Before tamoxifen induction, baseline cardiac dimensions and function were unchanged in Slc25a3 fl/fl-MCM mice as compared with wild type controls, and the placement of the loxP alleles in the Slc25a3 locus had no effect on PiC protein expression levels ( Figure 1b) . Slc25a3 deletion was induced in adult 2-month-old mice by administering tamoxifen (25 mg/kg/day) for 5 days. PiC protein expression, as assessed by western blot analysis, was reduced by 490% in heart mitochondria from Slc25a3 fl/fl-MCM mice as compared with controls, whereas other mitochondrial respiratory chain proteins and MPTP-related proteins such as CypD and the voltagedependent anion channel were unaffected (Figure 1b) .
Deletion of Slc25a3 causes impaired mitochondrial ATP synthesis. To examine the acute metabolic effects of Slc25a3 depletion, we isolated cardiac mitochondria 2 weeks after tamoxifen administration. Ablation of Slc25a3 over this 2-week time period resulted in a significant decrease in the rate of mitochondrial Pi uptake ( Figure 1c ) that was accompanied by a B45% decrease in the rate of mitochondrial ATP synthesis compared with mitochondria isolated from various control hearts (Figure 1d) . Notably, despite the impairment in mitochondrial ATP production, total cardiac tissue ATP levels were maintained ( Figure 1e , see below). To confirm that the mitochondrial ATP synthesis defect was a primary effect of Slc25a3 deletion as opposed to a consequence of respiratory chain dysfunction, we measured the activities of the individual respiratory complexes, which were unchanged in mitochondria isolated from hearts of Slc25a3 fl/fl-MCM mice after 2 weeks of tamoxifen administration (Figure 1f ). Mitochondrial reactive oxygen species (ROS) production was similarly unaffected, suggesting that uncoupling was not occurring in the absence of PiC protein (Figure 1g ). Together, these results indicate that acute Slc25a3 deletion causes impaired mitochondrial Pi uptake that leads to reduced mitochondrial ATP synthesis. Slc25a3 affects Ca 2 þ overload-induced MPTP opening and cell death. Mitochondrial Pi is a known regulator of the MPTP 26 and PiC itself has been suggested to serve as an obligate structural component of the MPTP. Here we used the Slc25a3 fl/fl-MCM model to genetically examine MPTP function in cardiac mitochondria lacking greater than 90% of PiC protein. Given that the acute 2-week depletion protocol described above did not adversely affect cardiac function, this time point was used to more carefully examine mitochondrial permeability transition and Ca 2 þ uptake. First, cardiac mitochondria isolated from Slc25a3 fl/fl-MCM mice and controls were assessed for their ability to undergo MPTPdependent swelling in response to Ca 2 þ overload and atractyloside (ATR), two known inducers of MPTP opening. Although both Ca 2 þ (200 mM) and ATR were able to induce swelling in mitochondria from hearts of Slc25a3 fl/fl-MCM mice, the extent of Ca 2 þ -induced swelling was reduced by approximately half in PiC-depleted mitochondria compared with controls (Figures 3a and c) . However, no reduction of swelling was observed with ATR because this agent induces MPTP formation through an effect on ANT activity, and more importantly, switching to a phosphate-free buffer with arsenate as the anion carrier eliminated this mild reduction in mitochondrial swelling from hearts of Slc25a3 fl/fl-MCM mice when challenged with 400 mM Ca 2 þ (Figure 3b ). These results suggest that PiC is not a direct pore-forming component of the MPTP complex. Importantly, cyclosporine (CsA), a known desensitizer of the MPTP, still inhibited Ca 2 þ -dependent swelling of heart mitochondria from all genotypes of mice (Figure 3a) . Collectively, these results suggest that although PiC is not required for MPTP formation, its absence can modulate the sensitivity of the MPTP to Ca 2 þ due to reduced Pi import/levels. We also investigated the ability of mitochondria from hearts of Slc25a3 fl/fl-MCM mice to take up Ca 2 þ . The data show that reduction in PiC protein resulted in substantially greater Ca 2 þ uptake capacity, similar to CsA treatment, compared with control mitochondria, further confirming that deletion of Slc25a3 renders mitochondria less sensitive to Ca 2 þ overload by desensitizing the MPTP (Figure 3d ).
To further investigate the ability of PiC to modulate MPTP activity, we also generated mouse embryonic fibroblasts (MEFs) from Slc25a3 fl/fl -targeted mice. These MEFs were treated with either an adenovirus-expressing Cre recombinase (AdCre) to induce Slc25a3 deletion, or a control adenovirus containing an irrelevant b-galactosidase complementary DNA (Adbgal), the former of which essentially resulted in complete loss of PiC protein (Figure 4a ). AdCre-mediated loss of PiC protein partially protected MEFs from a model of ionomycin-induced necrosis through MPTP formation, 22 although CsA was slightly more potent in providing protection (Figure 4b ). To directly assess MPTP opening in vivo, the calcein-AM-cobalt assay was performed in Slc25a3-deleted MEFs (Figure 4c, see methods) . Ionomycin-induced Ca 2 þ overload robustly reduced the mitochondrial calcein signal in control MEFs, which indicates MPTP opening (Figure 4c ). By contrast, mitochondrial calcein fluorescence was retained for a longer period of time in MEFs lacking PiC protein (Figure 4c ). Ablation of PiC in MEFs had no effect on mitochondrial membrane potential (Dc) as measured by Rhod-123 staining (Figure 4d) , nor was ROS production altered as measured by MitoSOX Red (Figure 4e ). These observations further suggest a role for PiC in modulating the MPTP in living cells.
Consistent with the results in MEFs lacking PiC protein, in which MPTP activity was partially desensitized, thereby conferring protection from programmed necrosis, we also observed partial protection from ischemia-reperfusion (I-R) injury in the hearts of Slc25a3 fl/fl-MCM mice. Two weeks following tamoxifen administration, Slc25a3 fl/fl-MCM , Slc25a3 fl/fl , and a-MHC-MCM mice were subjected to 1 h of cardiac ischemia followed by 24 h of reperfusion. Hearts were then perfused with Evans blue dye, stained with triphenyltetrazolium chloride to show viable myocardium in red, then imaged and analyzed for the amount of cardiac death (Figure 4f ). Although the area at risk was similar in all groups (Figure 4g ), Slc25a3 fl/fl-MCM mice displayed a significant reduction in the area of infarction as compared with controls ( Figure 4h ). Together, these results suggest that targeted deletion of Slc25a3 in cells or within the heart desensitizes the MPTP and reduces the extent of programmed necrosis.
Prolonged PiC deletion results in a severe mitochondrial cardiomyopathy. Although cardiac structure and function were relatively normal 2 weeks after Slc25a3 gene deletion with tamoxifen treatment, by 10 weeks these mice showed severe cardiac hypertrophy and myopathy (Figures 5a and b) . Heart weight to body weight ratios were increased by a marked 300% compared with controls ( Figure 5c ) with a corresponding B80% increase in myocyte cross-sectional areas (Figure 5d ). Echocardiography of hearts from Slc25a3 fl/fl-MCM mice 10 weeks after tamoxifen showed significantly reduced fractional shortening with greater left ventricular chamber dimension in diastole (Figures 5e and f) . However, Masson's trichrome-stained heart sections showed that loss of PiC did not lead to the development of fibrosis (Supplementary Figure S2a) , and correspondingly, there was no change in the percentage of TUNEL-positive Figure S2b) with PiC deletion, suggesting that cardiomyocyte death is not a major factor contributing to Slc25a3 deletion-induced cardiac dysfunction and hypertrophy. Further, examination of hearts from Slc25a3 fl/fl-MCM mice by electron microscopy showed extensive sarcomeric disarray with fragmented and disrupted mitochondria, as well as mitochondrial hyperproliferation (Figure 5g) . Indeed, direct quantification of mitochondrial DNA content confirmed mitochondrial expansion in the hearts of Slc25a3 fl/fl-MCM mice compared with controls ( Figure 5h ).
The bioenergetic profile of Slc25a3 fl/fl-MCM cardiac mitochondria 10 weeks after tamoxifen-induced PiC deletion mirrored that of the 2-week deletion time point, such that protein levels of Pic were down by greater than 95% (Supplementary Figure S3a) , and activities of individual respiratory chain complexes were unchanged (Supplementary Figure S3b) . However, Ca 2 þ -induced MPTP opening was again blunted in cardiac mitochondria lacking PiC, and mitochondrial Ca 2 þ uptake was similarly enhanced (Supplementary Figures S3c and d) . Consistent with these data, Slc25a3 fl/fl-MCM cardiac mitochondria continued to show (Figure 5i) . Surprisingly, similar to hearts with the acute 2-week PiC deletion (Figure 1e ), the total cardiac tissue ATP levels were unchanged with long-term PiC ablation, suggesting that the myocytes in these hearts were somehow compensating for the reduction in mitochondrialgenerated ATP (Figure 5j) . To investigate the mechanisms whereby PiC-depleted hearts maintain tissue ATP levels, we analyzed the expression profile of genes involved in glucose metabolism. We found that the cardiac glucose transporters Slc2a1 and Slc2a4 were strongly upregulated and expression of a wide range of glycolysis enzymes (HK1, PFKm, Gpi1, GAPDH, and PKM1) were significantly increased (Supplementary Figure S4) . In addition, expression of PDK4, an inhibitor of pyruvate entry into the tricarboxylic acid cycle, was greatly increased (Supplementary Figure S4) . These results suggest that glucose utilization through glycolysis is enhanced while mitochondrial metabolic flux is reduced as a direct mechanism of compensation for the reduction in mitochondrial ATP production. Collectively, we interpret these results to mean that loss of PiC protein from the heart compromises the ATP synthase's ability to generate adequate ATP, leading to a reactive mitochondrial expansion, upregulation in glycolytic glucose utilization, and induction of hypertrophy as an attempt to maintain cardiac function (see Discussion). Hence, cardiac-specific Slc25a3 fl/fl-MCM targeting generates a mouse model of metabolic, mitochondrial cardiomyopathy due to inadequate mitochondrial energy production.
Discussion
Similar to mitochondrial depletion of the MPTP regulator ANT1, 21 we found that cardiac mitochondria lacking PiC protein retained the ability to undergo permeability transition, suggesting that neither protein is a obligate component of the MPTP. However, loss of PiC protein significantly desensitized MPTP opening to Ca 2 þ , as well as led to greater Ca 2 þ uptake capacity at both 2 weeks and 10 weeks after protein deletion. Contrary to previous reports showing that siRNA-mediated partial depletion of PiC in cultured cells had no effect on MPTP opening, 27 we discovered that the complete loss of PiC protein in AdCre-treated Slc25a3 fl/fl primary MEFs resulted in a delayed dissipation of mitochondrial calcein signal in response to Ca In addition to the requirement of Pi for ATP synthesis, Pi is known to serve as an accompanying anion for mitochondrial Ca 2 þ uptake. 29, 30 Thus, one possibility for the Slc25a3 deletion-mediated desensitization of the MPTP is that mitochondrial Ca 2 þ uptake could be impaired. However, we observed that the protective effect of Slc25a3 deletion was not due to impaired mitochondrial Ca 2 þ uptake, as mitochondria from these gene-targeted mice exhibited an enhanced uptake ability. This finding suggests that PiC's role in regulating the MPTP is not through an effect on Ca 2 þ , but likely due to an effect on the MPTP itself. Indeed, mitochondrial swelling assays conducted in Pi-free buffer no longer showed a reduction in Ca 2 þ -induced swelling from Slc25a3-deleted hearts (Figure 3b ). This effect may very well be due to Pi, which is an allosteric regulator of the MPTP. Hence loss of PiC protein alters the influx rates of Pi in the microenvironment proximal to the ATPase synthase, which has been suggested to form part of the MPTP. Indeed, PiC, ANT, and the ATP synthase together form the ATP synthasome, 9 thereby more efficiently localizing the supply of substrates for ATP synthesis. Moreover, dimers of the ATP synthase itself, reconstituted in vitro, can form a pore with properties similar to the MPTP.
17 ANT1 is also a regulator of the MPTP in much the same way observed for PiC, such that mitochondria from either deficient mouse model take up more Ca 2 þ .
21
In addition to the finding that PiC modulates MPTP function, we also discovered that long-term deletion of Slc25a3 in cardiomyocytes results in the development of a severe cardiomyopathy that recapitulates the heart defects observed in humans with SLC25A3 deficiency. 10, 11 Mitochondrial dysfunction can lead to the development of a diverse spectrum of cardiac defects. The cardiomyopathy observed in the Slc25a3 fl/fl-MCM mice was specifically characterized by hypertrophy, ventricular dilation, decreased cardiac function, and mitochondrial hyperproliferation with disrupted ultrastructure. Interestingly, this cardiac phenotype is reproduced in mice lacking the gene encoding ANT1 protein. 13, 31 Further, the hypertrophic cardiomyopathy observed in SLC25A3-deficient patients 10, 11 is shared by patients with a recessive loss of function for the SLC25A4 gene encoding ANT1 protein. 12 Collectively, ANT and PiC may represent two sides of the same coin, as mitochondria lacking either of these proteins share a similar bioenergetic consequence of defective mitochondrial ATP synthesis, resulting in cardiomyopathy in mice and humans. The myocytes sense the reduction in ATP generation capacity from the mitochondria, which leads to a compensatory upregulation in total mitochondrial content and in genes involved in glucose utilization and ATP generation by glycolysis. However, how this lack of mitochondrial ATP generation is sensed by the hypertrophic growth signaling circuitry remains unknown. Our working hypothesis is that under in vivo conditions, the lack of PiC causes deficits in ATP concentrations in the heart at the level of the sarcomeres (very difficult to directly measure), leading to alterations in myofilament dynamics and altered tension/relaxation responsiveness. Altered myofilament tension can result in hypertrophic signals and activate disease pathways in the heart.
In conclusion, we have found that the acute genetic ablation of Slc25a3 desensitizes the MPTP to Ca 2 þ overload and confers protection against cardiac ischemic injury, although PiC is not itself a required component of the MPTP. Thus, PiC represents a possible new avenue to pursue therapeutics to prevent cardiomyocyte death through desensitization of the MPTP. However, as prolonged cardiac Slc25a3 deletion resulted in mitochondrial cardiomyopathy, our studies highlight the importance that such therapies are applied to shortterm injury events, such as after myocardial infarction injury when reperfusion is performed. Finally, as current therapies for mitochondrial diseases are limited, our phosphate carrierdeficient mouse model should provide insight into mitochondrial and energetics-based cardiomyopathies in humans in the hopes of identifying new treatments.
Materials and Methods
Animals. A targeting vector was designed for the Slc25a3 gene to insert loxP sites flanking exons 1 and 2 for homologous recombination in embryonic stem cells (SV129j background, KG1 cells). Correctly targeted embryonic stem cells were injected into C57Bl/6 blastocysts to generate chimeric mice, which were then bred with C57Bl/6 mice to obtain germline transmission and eventually homozygous targeted mice (Slc25a3 fl/fl ). Transgenic mice expressing the tamoxifen-inducible Cre recombinase under the control of a-MHC promoter were described previously. 32 Cre-mediated excision was induced at 2 months of age with tamoxifen (25 mg/kg/day i.p for 5 days). All animal experiments were approved and performed in accordance with Cincinnati Children's Hospital Medical Center's Institutional Animal Care and Use Committee.
Cardiac functional analyses, myocyte isolation, Ca 2 þ handling, and surgeries. Echocardiography was performed using a Hewlett Packard SONOS 5500 instrument (Palo Alto, CA, USA) with a 15-MHz transducer as previously described. 33 I-R injury was performed as previously described. 34 Adult cardiomyocytes were isolated as previously described 35 and myocyte contractility measurements were conducted by video edge detection (Photon Technology International, Birmingham, NJ, USA) as previously described. 36 Functional SR Ca 2 þ load was measured as the Ca 2 þ transient amplitude, resulting from the rapid administration of 20 mM caffeine as previously reported. 37 The decay time of this caffeine-induced contraction was used as an index for the kinetics of cytosolic Ca 2 þ removal. Cardiac ATP content was measured from liquid nitrogen snap frozen hearts using an ATP Determination Kit (Invitrogen, Carlsbad, CA, USA).
Mitochondrial isolation and analyses. Cardiac mitochondria were isolated in MS-EGTA buffer (225 mM mannitol, 75 mM sucrose, 5 mM Hepes, and 1 mM EGTA, pH 7.4) as previously described. 19 Mitochondrial phosphate uptake was measured using a [ 32 P] inhibitor-stop method as described previously. 38 ATP synthesis was measured using an ATP Determination Kit (Invitrogen) with modifications. 39 Mitochondrial swelling was assessed as a measure of light scattering at an absorbance of 540 nm as previously described. 19 Briefly, 250 mg mitochondria were incubated in swelling buffer (120 mM KCl, 10 mM Tris pH 7.4, 5 mM KH 2 PO 4 , 7 mM pyruvate, 1 mM malate, and 10 mM EDTA) and swelling was initiated with the addition of 200 mM CaCl 2 or 200 mM ATR in combination with 25 mM CaCl 2 . As a control, mitochondria were incubated with 1 mM CsA for 5 min before the start of the assay. For mitochondrial swelling in the presence of arsenate, mitochondria were incubated in buffer containing 120 mM KCl, 10 mM Tris pH 7.4, 5 mM KH 2 AsO 4 , 7 mM pyruvate, 1 mM malate, and 10 mM EDTA and swelling was initiated with the addition of 400 mM CaCl 2 . Mitochondrial Ca 2 þ uptake was measured using Calcium Green 5N (Molecular Probes, Eugene, OR, USA) in a Synergy 2 Multi-Mode Microplate Reader (BioTek, Winooski, VT, USA). 40 For this assay, mitochondria were sequentially challenged with additions of CaCl 2 (12.5 mM) and fluorescence was monitored. The activities of the individual respiratory chain complexes I-IV were measured in isolated cardiac mitochondria as previously described. 41 Complex V activity was measured spectrophotometrically as a function of ATP hydrolysis coupled to NADH oxidation using the Mitochondrial Complex V Activity Assay kit (EMD Millipore, Billerica, MA, USA). Mitochondrial free radical production was measured under energized conditions (7 mM pyruvate and 1 mM malate) using the Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Invitrogen) as described in. 42 To quantify mitochondrial DNA content, quantitative PCR was performed for the mt-Nd5 gene (mitochondrial) versus the 18S rRNA subunit (nuclear).
Cell culture and adenoviral infection. MEFs were isolated from Slc25a3 fl/fl E13.5 embryos and grown under conditions for culturing cells with mitochondrial dysfunction (Dulbeco's modified Eagle media containing 10% fetal bovine serum, 4.5 g/l glucose, 1 mM pyruvate, and 50 mg/ml uridine). 40, 43 MEFs were transduced with adenoviruses for 72 h. Cell death was induced with ionomycin as previously described. 22 Cell viability was measured using the Muse Cell Analyzer (EMD Millipore). Mitochondrial membrane potential was measured with Rhodamine-123 (Rhod-123, Life Technologies, Carlsbad, CA, USA). MEFs were incubated with 25 mM Rhod-123 and fluorescence was quantified by FACS analysis (BD FACSCalibur, BD Biosciences, Franklin Lakes, NJ, USA). Mitochondrial superoxide production was measured with the MitoSOX kit (Life Technologies). MEFs were stained with 5 mM MitoSOX and fluorescence was quantified by FACS analysis.
RT-PCR and TUNEL. Cardiac RNA was purified using the RNeasy Fibrous Tissue Mini Kit (Qiagen, Venlo, Netherlands) and cDNA was prepared using the First Strand Synthesis Kit (Invitrogen). Primer sequences for target genes were obtained from PrimerBank. 44 TUNEL staining was performed using the In Situ Cell Detection Kit (Roche, Basel, Switzerland).
Statistical analyses.
All results are presented as mean S.E.M. P-values o0.05 were considered significant as assessed by student's t-test.
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